Skip to main content

Table 4 Current and recent perioperative targeted therapy phase II trials for MIBC

From: Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

Institution Regimen Receptor target Setting Results/Status Trial ID
University of North Carolina Erlotinib EGFR Neoadjuvant Completed. Well tolerated. 35% (7/20) histologic downstaging preoperatively [26].  
University of North Carolina Erlotinib EGFR Neoadjuvant + Adjuvant Ongoing NCT00380029
MDACC Erlotinib EGFR Neoadjuvant Ongoing NCT00749892
Dendreon DN24-02 HER2R Adjuvant Ongoing. Updated results: 75% of 226 patients had HER2 expression in primary tumor, 84% in lymph nodes. APC activation for all 30 patients who have received 3 infusions of drug [27]. NCT01353222
Medical University of South Carolina Bevacizumab + GC and Bevacizumab + Paclitaxel# VEGFR-A Neoadjuvant + Adjuvant Ongoing. Preliminary results: 42% (5/12) postoperative complication rate. 31% (4/13) downstaging preoperatively [28]. NCT00268450
MDACC Bevacizumab + MVAC VEGFR-A Neoadjuvant Ongoing NCT00506155
FTRC Sorafenib + GC VEGFR + PDGFR* Neoadjuvant Unknown. NCT01222676
US Oncology Sunitinib + GC VEGFR + PDGFR* Neoadjuvant Terminated early due to patient toxicity. Only 9 MIBC patients studied for neoadjuvant therapy [29].  
MSKCC Sunitinib + GC VEGFR + PDGFR* Neoadjuvant Completed early due to limited study accrual. pT0 rate was low with combination [30]. NCT00847015
CCCC Sunitinib VEGFR + PDGFR* Neoadjuvant Completed, Results Unreported NCT00526656
Hoosier Oncology Group Dasatinib BCR/Abl^ Neoadjuvant Completed. Well tolerated. Follow-up pathology study: SFK expression downregulated in 77% (14/18) of patients [31, 32]. NCT00706641
University of Michigan Sunitinib VEGFR + PDGFR* Adjuvant Terminated due to poor accrual NCT01042795
Hoosier Oncology Group Sunitinib + GC VEGFR + PDGFR* Neoadjuvant Terminated due to patient toxicities NCT00859339
  1. MDACC = M.D. Anderson Cancer Center. FTRC = Fondazione C.N.R./Regione Toscana “G. Monasterio”, Pisa, Italy. MSKCC = Memorial Sloan-Kettering Cancer Center. CCCC = Case Comprehensive Cancer Center. GC = Gemcitabine and Cisplain. MVAC = Methotrexate, Vinblastine, Doxorubicin, Cisplatin. SFK = SRC Family Kinase. APC: Antigen Presenting Cell.
  2. *Sorafenib and Sunitinib target multiple receptor tyrosine kinases (RTKs) in addition to the aforementioned receptors.
  3. ^Dasatinib targets multiple tyrosine kinases.
  4. #This trial includes neoadjuvant bevacizumab with GC followed by surgery and adjuvant bevacizumab and paclitaxel.